Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 5/20 | 0.47 |
| ▸ | PRMT5 | O14744 | 4/20 | 0.43 |
| ▸ | WDR77 | Q9BQA1 | 4/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13573806 | 1.00 | NAMPT (0.47) | NAMPTPRMT5WDR77MAPK1PTPN1 | |
| SCHEMBL8191840 | 1.00 | NAMPT (0.47) | NAMPTPRMT5WDR77MAPK1PTPN1 | |
| SCHEMBL3748218 | 0.94 | PRMT5 (0.47) | NAMPTPRMT5WDR77MAPK1PTPN1 | |
| SCHEMBL2612174 | 0.94 | PRMT5 (0.47) | NAMPTPRMT5WDR77MAPK1PTPN1 | |
| SCHEMBL8261917 | 0.90 | DDB1 (0.43) | NAMPTPRMT5WDR77MAPK1PTPN1 | |
| SCHEMBL4655478 | 0.89 | DDB1 (0.42) | NAMPTPRMT5WDR77MAPK1PTPN1 | |
| SCHEMBL14963381 | 0.89 | DDB1 (0.42) | NAMPTPRMT5WDR77MAPK1PTPN1 | |
| SCHEMBL2805310 | 0.89 | DDB1 (0.42) | NAMPTPRMT5WDR77MAPK1PTPN1 | |
| SCHEMBL6913773 | 0.89 | DDB1 (0.42) | NAMPTPRMT5WDR77MAPK1PTPN1 | |
| SCHEMBL1634817 | 0.88 | DDB1 (0.42) | NAMPTPRMT5WDR77MAPK1PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090304631-A1 | HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR | PHENOMIX CORPORATION | 2009-12-10 | — | — | US | disclosed |
| EP-2029153-A2 | HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR | Phenomix Corporation (US) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007089618-A2 | HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR | PHENOMIX CORPORATION (US) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090304631-A1 | HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR | PREP, CTSC, PEPD | NAMPT 487/4885PRMT5 2265/4885WDR77 1100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.